LAG-3 drugs for Melanoma

2 tracked LAG-3 drugs in the Melanoma race. The class explanation lives on the LAG-3 page; the full indication pipeline across every mechanism is on the Melanoma page.

1 approved / phase 41 Phase 3

Head-to-head evidence: Fianlimab vs Relatlimab

The roster

← all LAG-3 drugs